IDYA at a glance
IDEAYA Biosciences, Inc. (IDYA, SEC CIK 1676725) filed its latest 10-K annual report on February 17, 2026, a 10-Q quarterly report on November 3, 2026, an 8-K current report on November 3, 2026 and Form 4 insider filings as recently as October 8, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), IDEAYA Biosciences, Inc. (IDYA) reported revenue of $218.7 million (up 3024.4% from FY2024) and a net loss of $113.7 million. Diluted EPS was -$1.28.
- As of September 30, 2026, 27 institutional investment managers tracked by SignalX reported holding IDEAYA Biosciences, Inc. (IDYA) shares worth $1.1 billion in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Hata Yujiro S on October 6, 2026 of 25,538 shares at $37.39 per share.
- In the last 90 days, IDYA insiders reported 0 open-market purchases ($0) and 2 open-market sales ($985K) on Form 4, a net sale of $985K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $218.7M
- +3024.4% vs prior year
- Insiders · 90 days
- 0 buys · 2 sells
- Net −$985K
- 13F holders
- 27 funds
- $1.1B · −2 vs prior quarter
- Latest 8-K
- Nov 3, 2026
- Item 2.02
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Core oncology precision medicine with focus on synthetic lethality and antibody-drug conjugates (ADCs) targeting molecularly defined solid tumors
- New Phase 3 neoadjuvant trial for darovasertib in primary uveal melanoma initiated, targeting eye preservation and vision improvement
- Servier exclusive license granted for darovasertib outside U.S., upfront payment $210M plus milestones up to $320M and royalties
- IDE849 DLL3 TOP1 ADC Phase 1 data in 100 patients shows 48% Grade 3+ TRAEs, median PFS 6.7 months, 83.3% ORR in brain metastasis at 2.4 mg/kg dose
- GSK terminating collaboration on Pol Theta inhibitor (IDE705) and WRN inhibitor (IDE275), programs transferring back for internal development
Risk Factors
- Regulatory risk: Servier License Agreement contract assets increased $6.0M, indicating dependency on this agreement's terms and regulatory compliance timing
- Macroeconomic threat: Operating cash used $71.1M in 2025 and $247.6M in 2024, showing high cash burn amid volatile financing environment
- Operational vulnerability: $10.4M accrued liabilities for CROs, CMOs, consultants, indicating heavy reliance on external research and manufacturing partners
- Financial risk: Net loss $113.7M in 2025 with $46.1M stock-based compensation, signaling significant operating losses and dilution risk
Management Discussion & Analysis
- Collaboration revenue $218.7M in 2025 vs $7.0M in 2024, up 3,024% driven by Servier License Agreement
- Net loss $113.7M in 2025 vs $274.5M in 2024; loss decreased 59%, operating expenses up 13% to $378.0M
- Research and development expenses $314.7M (+7%), general and administrative expenses $63.3M (+61%) in 2025
- Best performing segment: Collaboration revenue surge from Servier deal; worst: continued high R&D expenses, $98.1M on darovasertib
- Cash, cash equivalents, marketable securities $1.05B as of Dec 31, 2025; raised net $25M from equity ATM offering in 2025
- Outlook: Cash runway sufficient for 12+ months; expecting higher R&D expenses for clinical advancement; risk of funding shortfall if capital not raised
AI summary of the IDYA 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Risk Factors
- No material changes to risk factors disclosed in the February 17, 2026 Annual Report
- Carried-forward risks include potential adverse effects on business, financial condition, and future results
- Quarterly filing provides no newly triggered regulatory, operational, competitive, or financial risk વિગતો
Management Discussion & Analysis
- Quarterly collaboration revenue $10.2M, up 16% from $8.9M in Q2 2026
- Q3 net loss $125.7M, operating loss $137.6M, no product revenue
- Darovasertib highest Q3 clinical spend $35.1M, IDE161 lowest at $1.4M
- Cash, equivalents and marketable securities approximately $1.15B; operating cash used $256.9M
- Financing cash $364.1M, including $323.4M net follow-on offering proceeds; funding expected for at least twelve months
AI summary of the IDYA 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Q3 2026 financial results for the quarter ended September 30, 2026 announced
- Full earnings release furnished as Exhibit 99.1, containing the detailed results and management update
Item EX-99.1: Item EX-99.1
- Q3 2026 NDA submitted for darovasertib plus crizotinib in metastatic uveal melanoma, creating a potential near-term regulatory catalyst
- OptimUM-010 Phase 3 enrollment stopped, with estimated cost savings of $100-125 million redirected toward IDE849 and IDE892
Item EX-99.1: Item EX-99.1
- OptimUM-02 met its primary endpoint: median PFS 6.9 months versus 3.1 months, HR 0.42, p<0.0001
- NDA filing for darovasertib combination underway through FDA’s RTOR program, with completion expected in H2 2026
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 financial results announced for quarter ended June 30, 2026
- Full results and management commentary available in Exhibit 99.1
Item 8.01: Other Events
- Yujiro S. Hata elected Board Chairman effective June 16, 2026
- Terry Rosen, Ph.D. appointed Lead Independent Director
Item 5.07: Submission of Matters to a Vote of Security Holders
- All three Class I director nominees elected; terms run through 2029
- Director support varied, with Hampton receiving 56.7M votes for versus 16.3M withheld
AI summaries of IDYA 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for IDYA
Don't miss the next IDYA filing
- Alerts as it files. A push when IDYA files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut IDYA, by share count.
- Ask anything. An AI agent that reads every IDYA filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Hata Yujiro S | Sell | Oct 6, 2026 | 25,538 | $37.39 |
| Hata Yujiro S | M | Oct 6, 2026 | 26,338 | $4.31 |
| Hata Yujiro S | Sell | Oct 6, 2026 | 800 | $38.26 |
| Hata Yujiro S | M | Oct 6, 2026 | 26,338 | - |
| Ruiz Briseno Andres | M | Jul 7, 2026 | 9,550 | $12.86 |
| Ruiz Briseno Andres | Sell | Jul 7, 2026 | 9,550 | $40.01 |
| Ruiz Briseno Andres | M | Jul 7, 2026 | 9,550 | - |
| Stein Jeffrey | A | Jun 16, 2026 | 20,000 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $7.0M | $218.7M |
| Operating Income | -$134.4M | -$327.0M | -$159.3M |
| Net Income | -$113.0M | -$274.5M | -$113.7M |
| Op. Margin | - | -4671.1% | -72.8% |
| Net Margin | - | -3921.1% | -52.0% |
| Balance Sheet | |||
| Total Assets | $649.3M | $1.1B | $1.1B |
| Equity | - | $1.1B | $1.0B |
| ROE | - | -25.9% | -11.1% |
| Per Share | |||
| EPS | $-1.96 | $-3.36 | $-1.28 |
| Cash Flow | |||
| Operating CF | - | -$247.6M | -$71.1M |
| CapEx | - | $3.9M | $2.4M |
Source: XBRL data in IDEAYA Biosciences, Inc. (IDYA)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate IDYA share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 27 | $1.13B |
| Q2 2026 | 29 | $1.61B |
| Q1 2026 | 28 | $1.34B |
| Q4 2025 | 24 | $1.39B |
| Q3 2025 | 26 | $1.04B |
| Q2 2025 | 26 | $841.6M |
| Q1 2025 | 22 | $502.5M |
| Q4 2024 | 20 | $675.5M |
- BlackRock+655.3K (+7%)
- JPMorgan Chase & Co+243.5K (+91%)
- Goldman Sachs Group+222.4K (+18%)
- Vanguard Capital Management LLC+179.1K (+4%)
- Dimensional Fund Advisors+64.6K (+4%)
- State Street Corp−621.2K (-14%)
- T. Rowe Price Group−73.2K (-3%)
- Wells Fargo & Co−63.2K (-21%)
- Citigroup−48.2K (-43%)
- Morgan Stanley−9.1K (-0%)
- FMR LLC (Fidelity)−14.11M
- Citadel Advisors LLC−300.4K
- Millennium Management−10.5K
Source: 13F-HR filings on SEC EDGAR (aggregated from 202 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
IDYA filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Nov 3, 2026 | - | Analysis | - |
| 10-Q | Nov 3, 2026 | Sep 30, 2026 | Analysis | |
| 4 | Oct 8, 2026 | - | - | - |
| SC 13G | Aug 14, 2026 | - | - | |
| 10-Q | Aug 4, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 4, 2026 | - | Analysis | - |
| SC 13G | Jul 31, 2026 | - | - | |
| 4 | Jul 9, 2026 | - | - | - |
| 8-K | Jun 23, 2026 | - | Analysis | - |
| 4 | Jun 18, 2026 | - | - | - |
| 4 | Jun 18, 2026 | - | - | - |
| 4 | Jun 18, 2026 | - | - | - |
| 4 | Jun 18, 2026 | - | - | - |
| 4 | Jun 18, 2026 | - | - | - |
| 4 | Jun 18, 2026 | - | - | - |
| 8-K | Jun 10, 2026 | - | Analysis | |
| 8-K | Jun 3, 2026 | - | Analysis | |
| 8-K | Jun 1, 2026 | - | Analysis | |
| 8-K | May 5, 2026 | - | Analysis | - |
| 8-K | May 5, 2026 | - | Analysis | - |
| 10-Q | May 5, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | Apr 13, 2026 | - | Analysis | - |
| 8-K | Apr 9, 2026 | - | Analysis | - |
| 10-K | Feb 17, 2026 | Dec 31, 2025 | Analysis | |
| 8-K | Feb 17, 2026 | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
IDYA SEC filings: frequently asked questions
Are IDYA insiders buying or selling?
In the last 90 days, IDEAYA Biosciences, Inc. (IDYA) officers, directors and 10% owners reported no open-market purchases and 2 open-market sales worth $985,397 by 1 insider on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold IDYA stock?
As of September 30, 2026, the largest IDEAYA Biosciences, Inc. (IDYA) holders among the 13F filers tracked by SignalX were BlackRock ($366.9 million), Vanguard Capital Management LLC ($165.7 million), State Street Corp ($150.9 million), T. Rowe Price Group ($82.0 million), Morgan Stanley ($73.9 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was IDYA's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), IDEAYA Biosciences, Inc. (IDYA) reported revenue of $218.7 million (up 3024.4% from FY2024) and a net loss of $113.7 million. Diluted EPS was -$1.28. The figures come from the XBRL data in the 10-K.
What are the main risks in IDYA's latest 10-K?
In the 10-K filed February 17, 2026, IDEAYA Biosciences, Inc. (IDYA) flagged: Regulatory risk: Servier License Agreement contract assets increased $6.0M, indicating dependency on this agreement's terms and regulatory compliance timing. Macroeconomic threat: Operating cash used $71.1M in 2025 and $247.6M in 2024, showing high cash burn amid volatile financing environment. (AI summary of the Risk Factors section.)
What did IDYA report in its latest 8-K?
IDEAYA Biosciences, Inc. (IDYA) filed an 8-K on November 3, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 2026 financial results for the quarter ended September 30, 2026 announced.
What are the latest IDYA SEC filings?
IDEAYA Biosciences, Inc. (IDYA) filed its latest 10-K annual report on February 17, 2026, a 10-Q quarterly report on November 3, 2026, an 8-K current report on November 3, 2026 and a Form 4 insider filing on October 8, 2026.
What is IDYA's SEC CIK number?
IDEAYA Biosciences, Inc. (IDYA)'s SEC Central Index Key (CIK) is 1676725. EDGAR lists every IDYA filing under that number.
Ask anything about IDYA
The research agent reads IDYA's filings, financials, insider trades and 13F holders, then answers with sources.